Breast Cancer Treatment: NCCN Guideline Updates and Optimism at ASCO 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Primary and secondary end points were demonstrated in a phase 3 trial of subcutaneous marstacimab as treatment for patients with hemophilia A or B.

December 23rd 2024

In R/R Marginal Zone Lymphoma, 90% Alive at 2 Years After Liso-Cel

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

Listen

Marginal zone lymphoma | Image: Atlas of Hematological Cytology

June 24th 2025

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

In a cohort of TRANSCEND FL, the chimeric antigen receptor T-cell therapy liso-cel showed a 95% overall response rate in relapsed marginal zone lymphoma, offering hope for improved patient outcomes in challenging cases.

December 17th 2024

The Impact of High BMI on Outcomes, Treatment Efficacy in ALL

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

Listen

Doctor speaking to a female patient with obesity | Image credit: Studio Romantic - stock.adobe.com

Telehealth Model Reduces Hospital Admissions in COPD

High body mass index affects outcomes in acute lymphoblastic leukemia (ALL), highlighting the need for targeted interventions to improve patient survival rates and treatment efficacy.

A comprehensive home-based program integrating weekly telecounseling and individually tailored breathing exercise training reduced hospitalizations among patients with COPD. | Image credit: Ahmad - stock.adobe.com

Marstacimab Improved Key Bleeding Outcomes in Hemophilia A or B

Remote care reduced readmissions and improved functional outcomes in COPD in a recent study.

Related Content

June 26th 2025

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Primary and secondary end points were demonstrated in a phase 3 trial of subcutaneous marstacimab as treatment for patients with hemophilia A or B.

December 23rd 2024

In R/R Marginal Zone Lymphoma, 90% Alive at 2 Years After Liso-Cel

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

Listen

June 24th 2025

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

December 17th 2024

The Impact of High BMI on Outcomes, Treatment Efficacy in ALL

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

Listen

Telehealth Model Reduces Hospital Admissions in COPD

High body mass index affects outcomes in acute lymphoblastic leukemia (ALL), highlighting the need for targeted interventions to improve patient survival rates and treatment efficacy.